Selected Announcement of A-shares | Dajin Heavy Industry (002487.SZ) Signs Over 1.3 Billion Yuan Contract for Offshore Wind Power

Focus Today 1. Dajin Heavy Industry: Wholly-owned subsidiary signed a contract for a European offshore wind farm project worth 1.339 billion euros, accounting for 35.41% of the company's audited operating income in 2024. Dajin Heavy Industry announced that its wholly-owned subsidiary, Penglai Dajin, signed an exclusive supply contract for a transitional phase of a European offshore wind farm project with a European energy company. The total contract amount is approximately 1.339 billion euros, accounting for 35.41% of the company's audited operating income in 2024. 2. GigaDevice Semiconductor Inc.: Some directors and senior executives plan to reduce their holdings by a total of 249,000 company shares. GigaDevice Semiconductor Inc. announced that Vice Chairman and General Manager He Wei plans to reduce his holdings by no more than 63,800 shares, accounting for 0.0096% of the total share capital of the company; Director and Vice General Manager Hu Hong plans to reduce his holdings by no more than 106,400 shares, accounting for 0.0159% of the total share capital of the company; Vice General Manager Sun Guijing plans to reduce his holdings by no more than 48,200 shares, accounting for 0.0072% of the total share capital of the company; Vice General Manager Li Baokui plans to reduce his holdings by no more than 30,600 shares, accounting for 0.0046% of the total share capital of the company. The above-mentioned selling parties plan to reduce their holdings through centralized bidding due to personal fund needs, with the reduction period from December 15, 2025, to March 14, 2026. 3. Polyrocks Chemical Co., Ltd.: Investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws and regulations. Polyrocks Chemical Co., Ltd. announced that the company received the "Notice of Filing" from the China Securities Regulatory Commission on November 21, 2025, stating that the company is under investigation for suspected violations of information disclosure laws and regulations. Currently, all of the company's business activities are being carried out normally, and the company will actively cooperate with the relevant work of the China Securities Regulatory Commission and fulfill its information disclosure obligations in a timely manner. 4. Hubei Chaozhuo Aviation Technology: Controlling shareholder and actual controller planning significant matters, stock halted. Hubei Chaozhuo Aviation Technology announced that due to the controlling shareholder and actual controller Li Yihan, Li Guangping, and Wang Chunxiao planning significant matters that may result in a change of control of the company, trading of the company's stock has been suspended from the market opening on November 24, 2025. The suspension is expected to last for no more than 2 trading days. During the suspension period, the company will fulfill its information disclosure obligations based on the progress of the matter. After the relevant matters are confirmed, the company will promptly disclose relevant announcements and apply for the resumption of trading of its stock. 5. Jiangsu Hengrui Pharmaceuticals: SHR-1139 injection clinical trial approved, currently no similar drugs approved for market launch domestically or internationally. Jiangsu Hengrui Pharmaceuticals announced that its subsidiary Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the SHR-1139 injection. The clinical trial will be conducted in the near future. SHR-1139 injection is a therapeutic biological product independently developed by the company, and currently, there are no similar drugs approved for market launch domestically or internationally. As of now, the cumulative research and development investment for the project is approximately 100.13 million yuan. According to relevant laws and regulations, after obtaining the Drug Clinical Trial Approval Notification, clinical trials need to be conducted and approved by the National Medical Products Administration before production and launch. 6. HES Technology Group: Investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws and regulations. HES Technology Group announced that the company recently received the "Filing Notice" from the China Securities Regulatory Commission, stating that the company is under investigation for suspected violations of information disclosure laws and regulations. The company will actively cooperate with the investigation work, and all business activities are currently being carried out in an orderly manner. This investigation will not have a significant impact on the company's operations and management. 7. Shandong Golden Empire Precision Machinery Technology: Intends to cooperate with Dongpei Group on the business related to humanoid Siasun Robot & Automation harmonic reducer assembly and its key components. Shandong Golden Empire Precision Machinery Technology announced that the company signed a "Strategic Cooperation Letter of Intent" with Dongpei Industrial Co., Ltd., expressing their intention to cooperate on the business related to humanoid Siasun Robot & Automation harmonic reducer assembly and its key components, and to explore the feasibility of establishing a joint venture or other cooperation structure. The letter of intent does not involve a specific amount, and specific cooperation projects will be signed in a separate cooperation agreement. 8. Huiyu Pharmaceuticals: HYP-6589 tablet combination therapy obtains clinical trial application acceptance notification, currently no similar products approved for market launch domestically or internationally. Huiyu Pharmaceuticals announced that its wholly-owned subsidiary Huiyu Haiyue has received the "Acceptance Notification" issued by the National Medical Products Administration for the HYP-6589 tablet, which is used for combination therapy with osimertinib to treat target-driven gene-positive advanced non-small cell lung cancer. HYP-6589 tablet is a highly selective SOS1 small molecule inhibitor developed by the company's wholly-owned subsidiary Huiyu Haiyue, and its registration classification is Class 1 innovative drug. Currently, there are no similar products approved for market launch domestically or internationally. The research and development of new drugs have the characteristics of a long development cycle, high investment, and multiple stages from research to production, with the risk of delays and unexpected development results. 9. Humanwell Healthcare: Dimethylphenidate hydrochloride capsules market authorization application accepted, currently no domestic market approval for the drug or related products for import. Humanwell Healthcare announced that its holding subsidiary Yichang Renfu recently received the "Acceptance Notification" of the drug registration marketing approval application for dimethylphenidate hydrochloride capsules issued by the National Medical Products Administration. The drug is used to treat attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 and above. Currently, there is no domestic market approval for the drug, and there are no related products approved for import. Yichang Renfu has accumulated approximately 90 million yuan in research and development investment for this project. The acceptance of the drug registration marketing approval application indicates that the domestic production of the drug has entered the evaluation stage, and if it passes the evaluation and approval smoothly, it will enrich the company's product line and enhance its market competitiveness. Buybacks & Insider Trading 1. Shenzhen Goodix Technology: Plans to repurchase company shares worth 200 million to 400 million yuan for employee stock ownership plans. 2. Harbin Gloria Pharmaceuticals: Guoleifeng and Tibet Yupan collectively increase their holdings by 1.12%. 3. Bank of Nanjing: BNP Paribas increases its holdings by 1.04% of the company's shares. 4. Shanghai Yuyuan Tourist Mart: First repurchase 1 million A-shares, already paid 5.3864 million yuan. 5. Juneyao Airlines: Controlling shareholder Jun Yao Group plans to reduce its stake by less than 3%. 6. ZHONGHUAN CO., LTD.: Shareholders Chen Liang and Mu Chaoyong plan to reduce their stakes by 1.02% and 0.24%, respectively. Large Orders China Oil Hbp Science & Technology: Wins bid for 1.596 billion yuan Iraq oilfield production project. This article is reproduced from "Tencent Selection of Stocks", edited by GMTEight: Xu Wenqiang.